Aveo Pharmaceuticals (AVEO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
15.00 unch (unch) 01/19/23 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 15.00 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2021 | 12-2020 | 12-2019 | 12-2018 | 12-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -53,342 | -35,584 | 9,388 | -5,329 | -65,025 |
| Depreciation Amortization | 145 | -85 | -44 | 3 | 68 |
| Accounts receivable | -9,811 | N/A | N/A | -2,624 | 625 |
| Accounts payable and accrued liabilities | -667 | 1,914 | -2,033 | 1,063 | 250 |
| Other Working Capital | -10,013 | -240 | -3,611 | -2,216 | 8,377 |
| Other Operating Activity | 16,431 | -3,988 | -6,619 | -15,923 | 36,541 |
| Operating Cash Flow | $-57,257 | $-37,983 | $-2,919 | $-25,026 | $-19,164 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -16,866 | 18,067 | -17,917 | 18,579 | -10,402 |
| PPE Investments | N/A | -363 | N/A | N/A | N/A |
| Investing Cash Flow | $-16,866 | $17,704 | $-17,917 | $18,579 | $-10,402 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 25,000 | 5,329 | N/A | N/A | 5,000 |
| Debt Repayment | N/A | -6,497 | -3,834 | N/A | N/A |
| Common Stock Issued | 58,779 | 53,678 | 30,328 | 16,465 | 24,519 |
| Other Financing Activity | -875 | -255 | -300 | -540 | -100 |
| Financing Cash Flow | $82,904 | $52,255 | $26,194 | $15,925 | $29,419 |
| Beginning Cash Position | 61,761 | 29,785 | 24,427 | 14,949 | 15,096 |
| End Cash Position | 70,542 | 61,761 | 29,785 | 24,427 | 14,949 |
| Net Cash Flow | $8,781 | $31,976 | $5,358 | $9,478 | $-147 |
| Free Cash Flow | |||||
| Operating Cash Flow | -57,257 | -37,983 | -2,919 | -25,026 | -19,164 |
| Capital Expenditure | N/A | -363 | N/A | N/A | N/A |
| Free Cash Flow | -57,257 | -38,346 | -2,919 | -25,026 | -19,164 |